NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 9, 2024
NBIX$168.86+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in millions, except per share data) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $251.1 | $262.9 |
| Debt securities available-for-sale | 780.5 | 726.4 |
| Accounts receivable, net | 439.3 | 350.0 |
| Inventory, net | 38.3 | 35.1 |
| Other current assets | 97.8 | 79.1 |
| Total current assets | 1,607.0 | 1,453.5 |
| Deferred tax assets | 362.6 | 305.9 |
| Debt securities available-for-sale | 687.5 | 299.4 |
| Right-of-use assets | 276.5 | 87.0 |
| Equity securities | 161.9 | 102.1 |
| Property and equipment, net | 70.8 | 58.6 |
| Intangible assets, net | 35.5 | 37.2 |
| Other assets | 49.6 | 25.0 |
| Total assets | $3,251.4 | $2,368.7 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $448.8 | $347.6 |
| Convertible senior notes | 170.1 | 169.4 |
| Other current liabilities | 35.9 | 20.7 |
| Total current liabilities | 654.8 | 537.7 |
| Noncurrent operating lease liabilities | 258.3 | 93.5 |
| Other long-term liabilities | 106.3 | 29.7 |
| Total liabilities | 1,019.4 | 660.9 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,382.0 | 2,122.4 |
| Accumulated other comprehensive income (loss) | 7.0 | (7.9) |
| Accumulated deficit | (157.1) | (406.8) |
| Total stockholders’ equity | 2,232.0 | 1,707.8 |
| Total liabilities and stockholders’ equity | $3,251.4 | $2,368.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.